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Treatment of HT29 cells with the tumor promoting phorbol ester PMA resulted in an attenuation of VIP- 
stimulated CAMP production in intact cells and VIP-stimulated adenylate cyclase activity in cell membranes. 
PMA did not decrease the ability of cholera toxin and forskolin to elevate CAMP levels in intact cells. Fluor- 
ide-stimulated adenylate cyclase activity in HT29 cells homogenates was not affected by PMA. The maximal 
VIP binding capacity of homogenates prepared from HT29 cells treated with PMA was decreased by 50%. 
It is concluded that protein kinase C regulates VIP receptor function possibly through phosphorylation of 
the VIP receptor. 
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1. INTRODUCTION 
It is now well established that VIP exerts its 
physiological effects through binding to specific 
cell surface receptors and stimulation of adenylate 
cyclase [l]. In particular, the binding, molecular 
and functional properties of VIP receptors have 
been extensively studied in cellular and membrane 
systems derived from intestinal epithelium where 
VIP is thought to regulate water and electrolyte 
secretion [l]. A particularly useful model to study 
the molecular mechanisms of VIP action has been 
the HT29 cell line which is derived from a human 
colon adenocarcinoma [2]. This cell line has been 
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shown to possess high-affinity VIP receptors 
which are very efficiently coupled to adenylate 
cyclase activation [3]. 
Here, we present evidence that the tumor- 
promoting agent PMA, a potent activator of pro- 
tein kinase C [4], decreases VIP stimulation of 
adenylate cyclase and VIP-receptor binding in 
HT29 cells. It is proposed that protein kinase C 
modulates VIP action possibly through 
phosphorylation of the VIP receptor. 
2. MATERIALS AND METHODS 
2.1. Materials 
Porcine VIP was provided by Professor V. Mutt 
(Karolinska Institute, Stockholm). 12sI-labeled 
VIP (spec. act. 750 Ci/mmol) was prepared as 
described [5]. Forskolin, cholera toxin, IBMX, 
PMA and 4cr-PDD were from Sigma. 
2.2. Cell culture 
HT29 cells were obtained from Dr J. Fogh 
(Sloan Kettering Institute for Cancer Research, 
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Rye, NY). For measurements of cellular CAMP 
levels, cells were propagated in Falcon 75 cm2 
culture flasks and cultured for 3-5 days before use 
in Falcon 24-well plates as described 161. For 
adenylate cyclase activity measurements and 
binding experiments, cell culture and cell par- 
ticulate fraction preparation were performed as in 
]71. 
2.3. Cyclic AMP measurements 
Cyclic AMP levels in HT29 cells were measured 
by prelabeling the intracellular ATP pool with 
t3H]adenine and purifying cellular [3H]ATP and 
[3H]cAMP exactly as in [B]. VIP and forskolin 
were exposed to HT29 cells for 10 min in 25 mM 
Hepes-Tris buffer, pH 7.4 [B]. Cholera toxin was 
incubated for 1 h with HT29 cells in their culture 
medium. All incubations were carried out at 25°C 
with 1 mM IBM)<. Results were expressed as the 
percent of conversion of [‘H]ATP in [3H]cAMP. 
2.4. Adenylate cyclase activity and 
“‘I- V~P-~jnding assays 
VIP-stimulated adenylate cyclase activity in 
HT29 crude particulate fractions was assayed as in 
PI. ‘*?-VIP-binding studies were performed as 
described in [7]. 
2.5. Cell treatment with PMA 
In all experiments with the phorbol ester PMA, 
this agent at 100 ng/ml was incubated for 1 h at 
37°C with HT29 cells in their culture medium. The 
cells were then used either for CAMP 
measurements or for the preparation of crude par- 
ticulate fraction. 
3. RESULTS 
3.1. Effect of PkfA on VIP-stimulated CAMP 
production in HT29 ceils 
As reported in [3], VIP exerted a potent and very 
efficient stimulation of CAMP production in HT29 
cells (fig.1). Basal CAMP production was barely 
detectable with the technique used here to measure 
CAMP level. This made it difficult to estimate the 
maximal stimulation (over basal) induced by the 
peptide. Pretreatment of HT29 cells with PMA did 
not modify the EC50 value (2 nM) for VIP but 
resulted in a 40% decrease of VIP-induced CAMP 
accumulation at all peptide concentrations tested 
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Fig. 1. Concentration-response curves of VIP-stimulated 
CAMP production in control (0) or PMA-treated (0) 
HT29 cells. CAMP levels are expressed as the percent of 
conversion of [3H]ATP in [3H]cAMP. Data are means + 
SE from triplicate determinations in a typical 
experiment. Similar results were obtained in another 
experiment. 
(fig.1). In contrast, PMA did not decrease the 
ability of forskolin and cholera toxin to stimulate 
CAMP production in HT29 cells (table I). The 
biologically inactive phorbol ester rku-PDD had no 
significant effect on VIP-induced cAMP ac- 
cumulation in HT29 cells (not shown). 
3.2. Effect of PMA on VIP stimulation of 
adenylate cyclase activity in HT29 cell 
membranes 
VIP markedly stimulated adenylate cyclase ac- 
tivity in a particulate fraction prepared from HT29 
cells (fig.2). The EGO for VIP was 0.16 nM. 
Pretreatment of HT29 cells with PMA decreased 
the peptide potency by about 2-fold (EC50 0.3 nM) 
and also reduced by 20-30% the maximal extent 
of adenylate cyclase stimulation by VIP (fig.2). 
PMA was without significant effect on either basal 
(fig.2) or NaF-stimulated adenylate cyclase activi- 
ty. Indeed, the enzyme activity stimulated by 
10 mM NaF was 1340 pmol cAMP/min per mg 
protein in control membranes and 1370 pmol 
cAMP/min per mg protein in membranes prepared 
from cells pretreated with PMA. 
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Table 1 
Effect of PMA on forskolin- and cholera toxin- 
stimulated CAMP production in HT29 ceils 
Control PMA 
VIP 0.03 .uM 100 63.6 f 14.0 
Forskolin IlrM 13.1 + 1.4 13.7 f 1.6 
10 FM 70.7 If: 4.0 86.8 & 12.1 
100 PM 258.6 rt 26.3 226.3 f 16.2 
Cholera 0.01 pg/ml 11.4 + 0.9 13.5 + 0.9 
toxin 0.1 pg/ml 38.4 + 1.9 41.7 f 7.3 
1 pg/ml 157.8 + 8.7 161.2 f 7.7 
Results are expressed as percent of CAMP production 
induced by a maximally effective concentration of VIP. 
Basal CAMP production in this series of experiments was 
less than 1% of the maximal stimulation by VIP. Each 
value is the mean + SE from 3-4 determinations 
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Fig.2. Concentration-response curves of VIP-stimulated 
adenylate cyclase activity in membranes prepared from 
control (0) or PMA-treated (0) HT29 cells. Enzyme 
activity is expressed in pmol/min per mg membrane 
protein. Data are means f SE from two experiments 
with triplicate determinations in each experiment. 
3.3. Effect of PMA on VIP binding to NT29 cell 
membranes 
Competitive inhibition of ‘%VIP binding by 
increasing concentrations of unlabeled VIP was 
performed in particulate fractions from control or 
PMA-treated HT29 cells (fig.3A). The phorbol 
ester decreased ‘251-VIP binding by about 50% at 
all unlabeled VIP concentrations. Scatchard 
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Fig.3. Competitive inhibition of “?-VIP binding by 
unlabeled VIP in homogenates of control (0) or PMA- 
treated (0) HT29 cells. In A, the ratio of bound over 
free (B/F) ligand concentration is plotted as a function 
of VIP concentration. Data are means f SE from four 
experiments with duplicate determinations in each 
experiment. In B, the results are plotted according to 
Scatchard and were fitted by linear regression analysis. 
analysis of data derived from 4 independent ex- 
periments (fig.3B) revealed that PMA did not 
modify the affinity of VIP for its receptors (& 
values of 0.17 + 0.09 and 0.16 + 0.09 nM in mem- 
branes from control and PMA-treated cells, 
respectively) but decreased maximal binding 
capacity by about 50% @Lax values of 200 + 45 
and 103 of: 22 fmol/mg protein in membranes from 
control and PMA-treated cells, respectively), It 
was checked that when added to a particulate frac- 
tion prepared from control HT29 cells, PMA did 
not interfere with “‘I-VIP binding (not shown). 
4. DISCUSSION 
The present data clearly show that treatment of 
HT29 cells with the phorbol ester PMA impairs 
VIP-induced increase in cellular CAMP levels and 
VIP-stimulated adenylate cyclase activity in cell 
membranes. It is now well established that the 
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stimulation of adenylate cyclase by VIP in HT29 
cells and other cell types involves three protein 
components in the plasma membrane: the VIP 
receptor, the catalytic unit of adenylate cyclase and 
the GTP-binding protein N, which couples the VIP 
receptor to the catalytic unit [ 11. Thus, impairment 
of any of these three components by PMA could 
lead to an attenuation of VIP-stimulated adenylate 
cyclase activity. Several lines of evidence establish 
that PMA produces its effects at the level of VIP 
receptors. (i) Cholera toxin is known to stimulate 
CAMP production by promoting ADP- 
ribosylation of the a-subunit of N, [lo]. Similarly, 
F- has been reported to activate adenylate cyclase 
through an interaction with N, [lo]. In the present 
study, PMA failed to attenuate the action of these 
compounds. (ii) Forskolin stimulates adenylate 
cyclase activity in intact cells or cell membrane 
preparations by interacting directly with the 
catalytic unit [ll]. Again, PMA did not inhibit 
forskolin-stimulated CAMP production in HT29 
cells. (iii) Finally, treatment of HT29 cells with 
PMA resulted in a 50% loss of VIP receptors as 
measured in cell membranes using “‘I-VIP. 
Altogether, these data indicate that the ability of 
PMA to decrease VIP-induced stimulation of 
adenylate cyclase does not involve an effect of the 
phorbol ester on either N, or the catalytic unit. 
Rather, they point to a PMA-initiated process that 
leads to VIP receptor down-regulation, which in 
turn decreases VIP responsiveness in HT29 cells. 
The tumor-promoting phorbol esters such as 
PMA are thought to exert their effect through ac- 
tivation of protein kinase C [4]. Phorbol esters can 
substitute for diacylglycerol, the physiological ac- 
tivator of protein kinase C produced from 
receptor-mediated breakdown of phosphatidyl- 
inositol 4,5-bisphosphate [12]. Recently, phorbol 
esters were reported to promote phosphorylation 
of insulin [ 131, epidermal growth factor [ 14,151 
and ,8-adrenergic [16,17] receptors. In the latter 
case, phosphorylation resulted in loss of adenylate 
cyclase sensitivity to &adrenergic agonists [ 16,171. 
It is therefore tempting to speculate that in HT29 
cells, PMA, through activation of protein kinase 
C, induces the phosphorylation of VIP receptors, 
which results in the inability of the phosphorylated 
receptors to bind VIP, and consequently in a 
decreased sensitivity of HT29 cells to the peptide. 
Whether or not this represents the actual 
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mechanism that leads to a loss of VIP binding in 
HT29 cells, the present data point to a possible role 
for protein kinase C in regulating VIP receptor 
function. 
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